Q2 FY2026 · ended Jun 30, 2026 · Revenue $794,711, +206.7% YoY · Filed Aug 14, 2026
Bio Essence Corp. (BIOE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $794,711 and net income of $270,077. As of Jun 30, 2026 it held $675 in cash and investments and $1.6 million in total debt.
Revenue
$794,711
+206.7% vs year-ago quarter
Net income
$270,077
+351.2% vs year-ago quarter
Operating cash flow
$59,650
-64.5% vs year-ago quarter
Free cash flow
—
EPS
$0.00
+100.0% vs prior quarter
Dividend per share
None
Shares outstanding
53.81M
+41.6% vs year-ago quarter
Net cash
$-1.56M
Q2 FY2026
Operating margin
52.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIOE (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Irvine, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1723059
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $794,711 | $500,537 | $1.5M | $136,800 | $259,123 |
| Operating income | $279,290 | $215,795 | $1.0M | $14,253 | $61,223 |
| Net income | $270,077 | $205,373 | $1.0M | $12,998 | $59,864 |
| Diluted EPS | — | — | — | — | $0.00 |
| Operating cash flow | $59,650 | -$411,970 | $1.2M | $186,973 | $167,797 |
| Total assets | $4.0M | $789,032 | $422,474 | $184,534 | $112,692 |
| Total liabilities | $1.7M | $2.2M | $2.5M | $3.3M | $3.2M |
| Stockholders' equity | $2.3M | -$1.4M | -$2.1M | -$3.1M | -$3.1M |
| Cash and investments | $675 | $36,177 | — | — | — |
| Total debt | $1.6M | $1.6M | $1.6M | $1.6M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Oct 23, 2026 | Oct 15, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Material agreement
|
May 19, 2026 | Apr 24, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
Apr 24, 2026 | Apr 24, 2026 |
| 10-K | Annual report | Mar 27, 2026 | Dec 31, 2025 |
All 87 Bio Essence Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.